{"id":62919,"date":"2025-03-21T05:53:09","date_gmt":"2025-03-21T05:53:09","guid":{"rendered":"https:\/?p=62919"},"modified":"2025-03-21T05:55:35","modified_gmt":"2025-03-21T05:55:35","slug":"spectral-medical-stock-forecast","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/","title":{"rendered":"Spectral Medical Stock Forecast &#038; Q4 2024 Earnings Preview"},"content":{"rendered":"<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/Canada\/TSX\/EDT\">Spectral Medical Inc (EDT:CA)<\/a> is a late stage theranostic company developing diagnostics and therapies for septic shock. Its lead product combines an Endotoxin Activity Assay with the Toraymyxin\u2122 hemoperfusion device to remove endotoxin from the bloodstream.<\/p>\n<p>Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor\u2019s premium features. Claim your <a href=\"https:\/\/www.stocktargetadvisor.com\/pricing?utm_source=menu&amp;utm_medium=web&amp;utm_campaign=new%20year\">discount<\/a> here!<\/p>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/pricing?utm_source=menu&amp;utm_medium=web&amp;utm_campaign=new%20year\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-62543 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2025\/03\/Pricing-Page-Banner-2.png\" alt=\"Spring Season Sale\" width=\"900\" height=\"200\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/Pricing-Page-Banner-2.png 900w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/Pricing-Page-Banner-2-300x67.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/Pricing-Page-Banner-2-150x33.png 150w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/Pricing-Page-Banner-2-768x171.png 768w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><\/a><\/p>\n<h2>Expected Quarterly Earnings Report of Spectral Med Inc:<\/h2>\n<ul>\n<li>Report date: before the market opens on Wednesday, March 26, 2025<\/li>\n<li>Quarter: fourth quarter 2024<\/li>\n<li>Consensus EPS loss: approximately C$0.04 per share<\/li>\n<li>Consensus revenue: roughly C$0.50 million<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/\"><img decoding=\"async\" class=\"aligncenter wp-image-62921 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2025\/03\/sta-analyst-rating-widget-2025-03-21T104102.487.png\" alt=\"\" width=\"494\" height=\"295\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/sta-analyst-rating-widget-2025-03-21T104102.487.png 494w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/sta-analyst-rating-widget-2025-03-21T104102.487-300x179.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/sta-analyst-rating-widget-2025-03-21T104102.487-150x90.png 150w\" sizes=\"(max-width: 494px) 85vw, 494px\" \/><\/a><\/p>\n<h2>Stock Target Advisor\u2019s Analysis on Spectral Med Inc:<\/h2>\n<p><strong>Overall Rating:<\/strong> Slightly Bullish<\/p>\n<h3>What We Like<\/h3>\n<ul>\n<li>High market capitalization within the Diagnostics &amp; Research sector<\/li>\n<li>Top quartile risk adjusted returns over 12 months<\/li>\n<li>Low volatility relative to peers<\/li>\n<li>Superior earnings growth over five years<\/li>\n<\/ul>\n<h3>What We Do Not Like<\/h3>\n<ul>\n<li>Trading at a premium on price to book value<\/li>\n<li>Negative operating cash flow in the past four quarters<\/li>\n<li>Negative free cash flow in the past four quarters<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a> also highlights Spectral\u2019s 62.96% total return over the past year, ranking it first in its sector, and cites a Mackie Research target price of CAD 2.50<\/p>\n<h2>Conclusion:<\/h2>\n<p>Investors will focus on enrollment progress in Spectral\u2019s pivotal Phase 3 Tigris trial and cash runway when Q4 results are released on March 26. With strong sector leadership and a bullish technical profile, the earnings report is a key catalyst for Spectral Medical\u2019s valuation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Spectral Medical Inc (EDT:CA) is a late stage theranostic company developing diagnostics and therapies for septic shock. Its lead product combines an Endotoxin Activity Assay&#8230;<\/p>\n","protected":false},"author":17,"featured_media":62922,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-62919","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Spectral Medical Stock Forecast &amp; Q4 2024 Earnings Preview<\/title>\n<meta name=\"description\" content=\"Discover Spectral Medical\u2019s stock forecast ahead of its Q4 2024 earnings report on March?26. Get consensus EPS, revenue estimates, and price target insights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spectral Medical Stock Forecast &amp; Q4 2024 Earnings Preview\" \/>\n<meta property=\"og:description\" content=\"Discover Spectral Medical\u2019s stock forecast ahead of its Q4 2024 earnings report on March?26. Get consensus EPS, revenue estimates, and price target insights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-21T05:53:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-21T05:55:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/STAs-Blog-Images-2025-03-21T105223.092.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1256\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Spectral Medical Stock Forecast &#038; Q4 2024 Earnings Preview\",\"datePublished\":\"2025-03-21T05:53:09+00:00\",\"dateModified\":\"2025-03-21T05:55:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/\"},\"wordCount\":251,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/\",\"name\":\"Spectral Medical Stock Forecast & Q4 2024 Earnings Preview\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2025-03-21T05:53:09+00:00\",\"dateModified\":\"2025-03-21T05:55:35+00:00\",\"description\":\"Discover Spectral Medical\u2019s stock forecast ahead of its Q4 2024 earnings report on March?26. Get consensus EPS, revenue estimates, and price target insights.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spectral Medical Stock Forecast &#038; Q4 2024 Earnings Preview\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Spectral Medical Stock Forecast & Q4 2024 Earnings Preview","description":"Discover Spectral Medical\u2019s stock forecast ahead of its Q4 2024 earnings report on March?26. Get consensus EPS, revenue estimates, and price target insights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/","og_locale":"en_US","og_type":"article","og_title":"Spectral Medical Stock Forecast & Q4 2024 Earnings Preview","og_description":"Discover Spectral Medical\u2019s stock forecast ahead of its Q4 2024 earnings report on March?26. Get consensus EPS, revenue estimates, and price target insights.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2025-03-21T05:53:09+00:00","article_modified_time":"2025-03-21T05:55:35+00:00","og_image":[{"width":2400,"height":1256,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/03\/STAs-Blog-Images-2025-03-21T105223.092.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Spectral Medical Stock Forecast &#038; Q4 2024 Earnings Preview","datePublished":"2025-03-21T05:53:09+00:00","dateModified":"2025-03-21T05:55:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/"},"wordCount":251,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/","name":"Spectral Medical Stock Forecast & Q4 2024 Earnings Preview","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2025-03-21T05:53:09+00:00","dateModified":"2025-03-21T05:55:35+00:00","description":"Discover Spectral Medical\u2019s stock forecast ahead of its Q4 2024 earnings report on March?26. Get consensus EPS, revenue estimates, and price target insights.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/spectral-medical-stock-forecast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Spectral Medical Stock Forecast &#038; Q4 2024 Earnings Preview"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/62919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=62919"}],"version-history":[{"count":3,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/62919\/revisions"}],"predecessor-version":[{"id":62925,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/62919\/revisions\/62925"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/62922"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=62919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=62919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=62919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}